Home / Business and Economy / Orbis Medicines Seals $1.4B Deal with Novo Nordisk

Orbis Medicines Seals $1.4B Deal with Novo Nordisk

17 Sep

Summary

Orbis Medicines and Novo Nordisk formed a drug discovery pact.
The deal is valued at up to $1.4 billion.
The collaboration focuses on oral therapies for cardiometabolic diseases.

Orbis Medicines announced on Thursday, September 17, 2026, a significant drug discovery and licensing agreement with Novo Nordisk. This collaboration is valued at up to $1.4 billion, signaling a major investment in novel therapeutic approaches.

The primary objective of this partnership is to develop oral therapies for cardiometabolic diseases. These conditions are currently often managed using injectable medications, presenting an opportunity for more patient-friendly alternatives.

This strategic alliance underscores a shared commitment to innovation in treating chronic diseases. The development of oral drugs could significantly improve treatment accessibility and patient adherence.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.